New York Times Feed

HEALTHCARE

Patient Safety Movement Foundation Appoints New Chairman; Announces Drive Toward Zero Preventable Patient Deaths By 2030March 12, 2020

Patient Safety Movement Foundation (PSMF) – a global non-profit dedicated to unifying those involved in the healthcare ecosystem, identifying challenges that are causing patient deaths, and creating actionable solutions to mitigate them – is pleased to announce the appointment of its new chairman of the board of directors – Michael A.E. Ramsay, MD, FRCA. It also reaffirms its commitment to patient health and safety with updates to its mission, vision and values; and reestablishes its goal of achieving ZERO preventable patient deaths by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005733/en/ As one of PSMF’s longest-standing board members, serving since 2013, Dr. Ramsay has been an advocate for patient safety in the anesthesia world since the 1980’s and embodies the values and principles......

Continue Reading >
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised GuidanceMarch 12, 2020

Regulatory News:

Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The company exceeded its raised guidance for full-year 2019 on both net sales and EBITDA.

FINANCIAL PERFORMANCE: STRONG SALES AND PROFIT GROWTH CONTINUES

Takeda Provides Update on TOURMALINE-MM2 Phase 3 TrialMarch 11, 2020

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients. The addition of ixazomib to lenalidomide and dexamethasone resulted in an improvement in median progression-free survival (PFS) of 13.5 months (35.3 months versus 21.8 months; hazard ratio [HR] 0.83; p=0.073); however, it did not meet the threshold for statistical significance. The safety profile associated with NINLARO from the TOURMALINE-MM2 trial was generally consistent with the existing prescribing information. Results from the TOURMALINE-MM2 study will be submitted to an upcoming medical congress. “There is a need for treatment options in transplant ineligible patients. We remain......

Continue Reading >
Sinterex named Best 3D-Printed Healthcare Products Manufacturer Middle EastMarch 11, 2020

Global Health & Pharma (GHP), a global information sharing platform & a multi-disciplinary members community announced winners of the 2019 Technology Awards this month and recognised Sinterex as Best 3D-Printed Healthcare Products Manufacturer – Middle East.

In its announcement, GHP said, “Technology is a great force for change across numerous industries, sectors and fields. In the global healthcare industry, it has become a"...

Continue Reading >
Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19March 9, 2020

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also studying whether Takeda’s currently marketed and pipeline products may be effective treatments for infected patients. SARS-CoV-2 is the virus that causes COVID-19. Hyperimmune globulins are plasma derived-therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections and may be a treatment option for COVID-19. As a leader in plasma-derived therapies with more than 75 years of experience in the development of plasma-derived products, Takeda has the expertise to research, develop, and manufacture a potential anti-SARS-CoV-2 polyclonal......

Continue Reading >
EU seeks united front to tackle medical shortages from virusMarch 8, 2020

(Petra)-- Fearing a possible shortage in masks and protective equipment to fight the new coronavirus, top European Union officials are urging members to put solidarity above national interests as the virus spreads quickly across the continent.

Speaking Friday after an urgent meeting in Brussels of health ministers from the 27-country bloc, crisis management commissioner Janez Lenarcic said EU nations are entitled to restrict exports of medical equipment but warned that such decisions could compromise the EU's"...

Continue Reading >
Five hospitals designated for quarantine, Covid-19 testing March 8, 2020

AMMAN — Five hospitals in the Kingdom's northern, central and southern regions have been designated to operate as centres for quarantine and sampling of suspected coronavirus (Covid-19) cases, the National Anti-Pandemic Committee said on Friday.

During a meeting headed by Minister of Health Saad Jaber to discuss the latest developments on the spread of the novel coronavirus, the committee, which includes representatives of the concerned"...

Continue Reading >
Egg Freezing Techniques Offering Women Flexibility on Their Motherhood Timeline Become Increasingly PopularMarch 8, 2020

In observance of International Women’s Day, Fakih IVF Fertility Center is rolling out a special campaign supporting all women and their choices. The campaign is running throughout March, across the center’s branches located in Abu Dhabi, Dubai and Al Ain.

With majority of women considering delaying pregnancy or choosing to embrace motherhood later in their lives, the various methods of fertility preservation available today give them"...

Continue Reading >
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung CancerMarch 7, 2020

– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients –

– Positive Opinion is Based on Data from Phase 3 ALTA-1L Trial, in which ALUNBRIG Demonstrated Superiority in both Overall and Intracranial Efficacy Compared to Crizotinib –

Takeda Pharmaceutical Company Limited"...

Continue Reading >
Takeda Completes Sale of Select OTC and Non-Core Assets to AcinoMarch 6, 2020

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for a total value in excess of $200 million USD. The divestment agreement was first announced in October 2019. The transaction includes approximately 30 select prescription pharmaceutical and OTC products. These products will continue to be made available by Takeda in other parts of the world. Close to 270 employees, primarily sales and marketing professionals supporting the portfolio, are also transitioning to Acino. The parties also entered into multi-year manufacturing and supply agreements, under which Takeda will continue to manufacture......

Continue Reading >